



Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive

**Externally-Led Patient-Focused Drug Development Meeting
November 2, 2022 | 10 a.m.-3 p.m. EDT**

Meeting livestream: www.sczaction.org/pfdd

Meeting Agenda

10-10:05 a.m.

Welcome

*Tim Franson, M.D., Meeting Moderator
Principal – Faegre Drinker Consulting*

*Paulie Benjamin, Meeting Co-Moderator
Schizophrenia Patient Advocate*

10:05-10:10 a.m.

Opening Remarks

*Mary Palafox, R.N.
Chair of the Board
Schizophrenia & Psychosis Action Alliance*

10:10-10:20 a.m.

Overview of Patient-Focused Drug Development

*Bernard Fischer, M.D.
Deputy Director, Division of Psychiatry, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration*

10:20-10:35 a.m.

Overview of Schizophrenia Symptoms and Treatment Approaches

*Matcheri Keshavan, M.D.
Department of Psychiatry, Beth Israel Deaconess Medical Center
Stanley Cobb Professor of Psychiatry, Harvard Medical School*

10:35-10:50 a.m.

Discussion Format Overview and Demographic Polling

*Tim Franson, Meeting Moderator
Paulie Benjamin, Meeting Co-Moderator*

Topic 1: Symptoms of Schizophrenia and Impact on Daily Life

10:50-11:15 a.m. **Panel Remarks from People Living with Schizophrenia or Caregivers**

11:15 am.-12:30 p.m. **Facilitated Discussion**

12:30-1 p.m. **Break**

Topic 2: Views on Current Approaches to Treatment and Future Treatments

1-1:25 p.m. **Panel Remarks from People Living with Schizophrenia or Caregivers**

1:25-2:40 p.m. **Facilitated Discussion**

2:40-2:50 p.m. **Pre-Meeting Survey Data Presentation**
Terry Frangiosa, M.B.A.
Board Member
Schizophrenia & Psychosis Action Alliance

2:50-3 p.m. **Closing Remarks**
Tim Franson, Meeting Moderator
Paulie Benjamin, Meeting Co-Moderator